Skip to main content

Table 2 Biometric and hemodynamic parameters of high-dose liraglutide groups with/without 10% glucose intake

From: GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy

 High-dose liraglutide treatment (J2N-k)High-dose liraglutide treatment with 10% glucose intake (J2N-k)
(n = 13)(n = 12), (n = 5 for LV pressure)
Biometry
 Body weight, g107 ± 2.8120.2 ± 2.8
 Heart, g0.72 ± 0.040.61 ± 0.03*
 Heart/BW, mg/g6.7 ± 0.45.1 ± 0.2
 Lung, g0.85 ± 0.090.71 ± 0.03
 Lung/BW, mg/g7.9 ± 0.95.9 ± 0.2
Echocardiography
 HR, beats/min376 ± 19399 ± 8
 LVEDD, mm7.4 ± 0.17.1 ± 0.1
 LVESD, mm6.3 ± 0.25.7 ± 0.1
 LV ejection, %0.35 ± 0.020.45 ± 0.02
 LV FS, %0.15 ± 0.010.20 ± 0.01*
 LV AW, mm0.67 ± 0.010.79 ± 0.03
 LV PW, mm0.79 ± 0.020.87 ± 0.05
Intracardiac pressure
 Positive dP/dt, mmHg/s2501 ± 2904699 ± 981*
 Negative dP/dt, mmHg/s− 1700 ± 171− 2128 ± 357
 EDP, mmHg13.8 ± 2.812.8 ± 2.36
 Max pressure, mmHg66.1 ± 5.576.2 ± 6.31
 Min pressure, mmHg9.4 ± 2.07.3 ± 0.87
  1. All values were expressed as mean ± SEM. *p > 0.05, p > 0.005